Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.

The Journal of investigative dermatology - 1 Jun 2021

Fukumoto Takeshi, Lin Jianhuang, Fatkhutdinov Nail, Liu Pingyu, Somasundaram Rajasekharan, Herlyn Meenhard, Zhang Rugang, Nishigori Chikako

Abstract excerpt

The SWI/SNF chromatin remodeler family includes the BAF and PBAF complexes. ARID2, encoding a PBAF complex subunit, is frequently mutated in melanoma independently of BRAF/RAS mutations. Emerging evidence shows that SWI/SNF complexes regulate tumor immunity; for instance, the loss of PBRM1, another PBAF complex subunit, enhances susceptibility to immune checkpoint inhibitors in melanoma. Notably, ARID2 mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Knockout Techniques

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Signal Transduction

Share to Skin Neoplasms

Share to Transcription Factors

Source

Identifiers

PMID: 33333124
DOI: 10.1016/j.jid.2020.11.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.PMID 33333124Read ↗

ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.Semantic proximity Read ↗

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.Semantic proximity Read ↗

ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical applicationSemantic proximity Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

Mi-2β promotes immune evasion in melanoma by activating EZH2 methylationSemantic proximity Read ↗

Role of Histone Deacetylases in Drug-Resistant Melanoma: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine ExpressionSemantic proximity Read ↗

Mi-2β-targeted inhibition induces immunotherapy response in melanomaSemantic proximity Read ↗

Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanomaSemantic proximity Read ↗

SOX10 Regulates Melanoma Immunogenicity through an IRF4–IRF1 AxisSemantic proximity Read ↗

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.Semantic proximity Read ↗

Decitabine suppresses MDSC-induced immunosuppression through dual functional mechanism and inhibits melanoma metastasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.